This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Abivertinib
- DrugBank Accession Number
- DB15327
- Background
Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).1 It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).2
Abivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.2,3 The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.4
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Abivertinib (DB15327)
- Weight
- Average: 487.539
Monoisotopic: 487.213201268 - Chemical Formula
- C26H26FN7O2
- Synonyms
- Abivertinib
- External IDs
- A610
- AC-0010
- AC0010
- ACEA100610
- EX-ACEA0010
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AEpidermal growth factor receptor inhibitorHumans ATyrosine-protein kinase BTK inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Abivertinib maleate Y50131AMFJ 1822357-78-7 QITOONQVTOGMOJ-IUJXYRIYSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- CER0OPG92L
- CAS number
- 1557267-42-1
- InChI Key
- UOFYSRZSLXWIQB-UHFFFAOYSA-N
- InChI
- InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
- IUPAC Name
- N-{3-[(2-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
- SMILES
- CN1CCN(CC1)C1=C(F)C=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3C=CNC3=N2)C=C1
References
- General References
- Sorrento Therapeutics: Abivertinib [Link]
- Sorrento Therapeutics: Abivertinib COVID-19 Trial [Link]
- NCT04440007: Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 (SOC) [Link]
- Targeted Oncology: FDA Clears Phase 2 Study of Abivertinib in Hospitalized Patients With COVID-19 [Link]
- External Links
- ChemSpider
- 57490375
- BindingDB
- 294480
- ChEMBL
- CHEMBL4297865
- ZINC
- ZINC000142081723
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Treatment Advanced Non-Small Cell Lung Cancer (NSCLC) 1 3 Withdrawn Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 2 2 Not Yet Recruiting Treatment Prostate Cancer / Prostate Cancer Metastatic 1 2 Recruiting Treatment Non-small Cell Lung Carcinoma (Adenocarcinoma) 1 2 Unknown Status Treatment Metastatic Non-Small Cell Lung Cancer 1 1 Completed Treatment Non-small Cell Lung Carcinoma (Adenocarcinoma) 2 1 Terminated Treatment Non-Small Cell Lung Cancer (NSCLC) 1 1 Unknown Status Treatment B-Cell Lymphoma 1 1, 2 Active Not Recruiting Treatment Metastatic Non-Small Cell Lung Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0276 mg/mL ALOGPS logP 4.33 ALOGPS logP 4.82 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 12.6 Chemaxon pKa (Strongest Basic) 7.25 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 98.41 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 138.95 m3·mol-1 Chemaxon Polarizability 52.34 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Ubiquitin protein ligase binding
- Specific Function
- Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
- Gene Name
- EGFR
- Uniprot ID
- P00533
- Uniprot Name
- Epidermal growth factor receptor
- Molecular Weight
- 134276.185 Da
References
- Sorrento Therapeutics: Abivertinib [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Protein tyrosine kinase activity
- Specific Function
- Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately le...
- Gene Name
- BTK
- Uniprot ID
- Q06187
- Uniprot Name
- Tyrosine-protein kinase BTK
- Molecular Weight
- 76280.71 Da
References
- Sorrento Therapeutics: Abivertinib [Link]
Drug created at May 20, 2019 15:15 / Updated at February 21, 2021 18:55